Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW221043 in Advanced Solid Tumors
NCT07719920Phase 1Recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HW221043 in solid tumor, sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute. Primary endpoints: Adverse Events or Serious Adverse Events at 2 years and Dose Limited Toxicity at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
HW221043
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07719920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719920.